Role of the angiotensin II type-2 receptor in radiation nephropathy

被引:20
作者
Cohen, Eric P.
Fish, Brian L.
Sharma, Mukut
Li, X. Allen
Moulder, John E.
机构
[1] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA
关键词
D O I
10.1016/j.trsl.2007.03.004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Experimental studies have shown that blockade of the angiotensin II type- 1 (AT(1)) receptor is effective in the mitigation and treatment of radiation -induced chronic renal failure. Also, blockade of the angiotensin II type-2 (AT(2)) receptor with PD- 123319 also had a modest, but reproducible, beneficial effect in experimental radiation nephropathy, and it might augment the efficacy of an AT, blocker (L- 158,809). Those studies could not exclude the possibility that the effects of AT(2) blockade were nonspecific. The current studies confirm the efficacy of AT(2) blockade for mitigation of experimental radiation nephropathy but paradoxically find no detectable level of AT(2) receptor binding in renal membranes. However, the results of a bioassay showed that the circulating levels of the AT(2) blocker were orders-of -magnitude too low to block AT, receptors. The effect of AT(2) blockade in radiation nephropathy cannot be explained by binding to the AT, receptor, and the efficacy of the AT, blockade in the same model cannot be explained by unopposed overstimulation of the AT(2) receptor.
引用
收藏
页码:106 / 115
页数:10
相关论文
共 43 条
[31]   Brief pharmacological intervention in experimental radiation nephropathy [J].
Moulder, JE ;
Fish, BL ;
Cohen, EP .
RADIATION RESEARCH, 1998, 150 (05) :535-541
[32]  
MOULDER JE, IN PRESS CURR PHARM
[33]   Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury [J].
Moulder, John E. ;
Cohen, Eric P. .
SEMINARS IN RADIATION ONCOLOGY, 2007, 17 (02) :141-148
[34]  
NAVAR LG, 1994, J AM SOC NEPHROL, V5, P1153
[35]   Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition [J].
Oikawa, T ;
Freeman, M ;
Lo, W ;
Vaughan, DE ;
Fogo, A .
KIDNEY INTERNATIONAL, 1997, 51 (01) :164-172
[36]   DISTRIBUTION OF ANGIOTENSIN-II RECEPTOR SUBTYPES IN RAT AND HUMAN KIDNEY [J].
SECHI, LA ;
GRADY, EF ;
GRIFFIN, CA ;
KALINYAK, JE ;
SCHAMBELAN, M .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (02) :F236-F240
[37]  
SIEGL PKS, 1992, J PHARMACOL EXP THER, V262, P139
[38]   AT1 and AT2 receptor in the kidney:: Role in health and disease [J].
Siragy, HM .
SEMINARS IN NEPHROLOGY, 2004, 24 (02) :93-100
[39]   Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries - Report of the NCI workshop, December 3-4, 2003 [J].
Stone, HB ;
Moulder, JE ;
Coleman, CN ;
Ang, KK ;
Anscher, MS ;
Barcellos-Hoff, MH ;
Dynan, WS ;
Fike, JR ;
Grdina, DJ ;
Greenberger, JS ;
Hauer-Jensen, M ;
Hill, RP ;
Kolesnick, RN ;
MacVittie, TJ ;
Marks, C ;
McBride, WH ;
Metting, N ;
Pellmar, T ;
Purucker, M ;
Robbins, ME ;
Schiestl, RH ;
Seed, TM ;
Tomaszewski, JE ;
Travis, EL ;
Wallner, PE ;
Wolpert, M ;
Zaharevitz, D .
RADIATION RESEARCH, 2004, 162 (06) :711-728
[40]   Angiotensin II stimulates both aldosterone secretion and DNA synthesis via type 1 but not type 2 receptors in bovine adrenocortical cells [J].
Tanabe, A ;
Naruse, M ;
Arai, K ;
Naruse, K ;
Yoshimoto, T ;
Seki, T ;
Imaki, T ;
Kobayashi, M ;
Miyazaki, H ;
Demura, H .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (10) :668-672